PDCD1 and neoplasm: Unexpectedly, tumour recurrence was observed in 66.7% (4/6) of the anti‐PD1 antibody‐treated group after discontinuation for more than 2 weeks, while no relapse occurred in the combined therapy group even 2 months after withdrawal of medication (Figure 5B,D).